ATE226831T1 - Impfstoff gegen mittelohrentzündung - Google Patents

Impfstoff gegen mittelohrentzündung

Info

Publication number
ATE226831T1
ATE226831T1 AT94922428T AT94922428T ATE226831T1 AT E226831 T1 ATE226831 T1 AT E226831T1 AT 94922428 T AT94922428 T AT 94922428T AT 94922428 T AT94922428 T AT 94922428T AT E226831 T1 ATE226831 T1 AT E226831T1
Authority
AT
Austria
Prior art keywords
fimbrin
vaccine against
ear inflammation
entire ear
against entire
Prior art date
Application number
AT94922428T
Other languages
English (en)
Inventor
Pappachan E Kolattukudy
Lauren O Bakaletz
Tatiana Sirakova
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Application granted granted Critical
Publication of ATE226831T1 publication Critical patent/ATE226831T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
AT94922428T 1993-05-18 1994-05-12 Impfstoff gegen mittelohrentzündung ATE226831T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6544293A 1993-05-18 1993-05-18
PCT/US1994/005477 WO1994026304A1 (en) 1993-05-18 1994-05-12 Otitis media vaccine

Publications (1)

Publication Number Publication Date
ATE226831T1 true ATE226831T1 (de) 2002-11-15

Family

ID=22062752

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94922428T ATE226831T1 (de) 1993-05-18 1994-05-12 Impfstoff gegen mittelohrentzündung

Country Status (9)

Country Link
US (3) US5766608A (de)
EP (2) EP1300156A3 (de)
JP (1) JP3429313B2 (de)
AT (1) ATE226831T1 (de)
DE (1) DE69431624T2 (de)
DK (1) DK0699076T3 (de)
ES (1) ES2185658T3 (de)
PT (1) PT699076E (de)
WO (1) WO1994026304A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE226831T1 (de) 1993-05-18 2002-11-15 Univ Ohio State Res Found Impfstoff gegen mittelohrentzündung
EP0702516A4 (de) * 1993-06-01 1998-04-22 Life Technologies Inc Genetische immunisierung mit kationischen lipiden
US5770213A (en) 1994-05-05 1998-06-23 American Cyanamid Company Purified nontypable haemophilus influenzae P5 protein as a vaccine for nontypable haemophilus influenzae infection
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
GB9812613D0 (en) * 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
ATE383331T1 (de) * 1998-11-12 2008-01-15 Invitrogen Corp Transportreagentien
DE60043930D1 (de) 1999-03-19 2010-04-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0117762D0 (en) * 2001-07-20 2001-09-12 Glaxosmithkline Biolog Sa Novel compounds
EP2255826B1 (de) 2002-08-02 2016-04-13 GlaxoSmithKline Biologicals S.A. Neisseria impfstoffzusammensetzungen die eine kombination von antigenen enthalten
EP1556477B1 (de) 2002-11-01 2017-08-09 GlaxoSmithKline Biologicals s.a. Trockungsverfahren
US8574596B2 (en) 2003-10-02 2013-11-05 Glaxosmithkline Biologicals, S.A. Pertussis antigens and use thereof in vaccination
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
DE602006018308D1 (de) * 2005-07-08 2010-12-30 Nationwide Childrens Hospital Chimärer impfstoff für haemophilus influenzae-induzierte infektion
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
LT2384765T (lt) 2005-12-22 2017-01-10 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae vakcina
EP1973933B1 (de) 2006-01-17 2020-06-24 Forsgren, Arne Neues oberflächenexponiertes haemophilus influenzae-protein (protein e; pe)
BRPI0813307C1 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, processo para fabricar a vacina
US9127306B2 (en) * 2008-02-15 2015-09-08 Life Technologies Corporation Methods and apparatuses for nucleic acid shearing by sonication
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
WO2011110636A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
WO2012170356A1 (en) 2011-06-04 2012-12-13 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
AU2014225330B2 (en) 2013-03-08 2018-11-01 Lauren O. Bakaletz Transcutaneous dosage formulation
CN106572974B (zh) 2014-07-15 2021-04-23 生命技术公司 用于将分子有效递送到细胞的具有脂质聚集体的组合物和方法
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
US11591364B2 (en) 2017-12-01 2023-02-28 Glaxosmithkline Biologicals Sa Saponin purification
JP2021533162A (ja) 2018-08-07 2021-12-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロセス及びワクチン
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
JP2022535091A (ja) 2019-06-05 2022-08-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
DK219084D0 (da) * 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
US5110908A (en) * 1986-12-31 1992-05-05 Praxis Biologics, Inc. Haemophilus influenzae peptides and proteins
ATE226831T1 (de) 1993-05-18 2002-11-15 Univ Ohio State Res Found Impfstoff gegen mittelohrentzündung

Also Published As

Publication number Publication date
US6030626A (en) 2000-02-29
JPH09500104A (ja) 1997-01-07
DE69431624T2 (de) 2003-07-10
WO1994026304A1 (en) 1994-11-24
ES2185658T3 (es) 2003-05-01
DK0699076T3 (da) 2003-03-03
EP0699076B1 (de) 2002-10-30
EP1300156A2 (de) 2003-04-09
EP0699076A1 (de) 1996-03-06
EP0699076A4 (de) 1999-09-08
EP1300156A3 (de) 2003-05-07
DE69431624D1 (de) 2002-12-05
PT699076E (pt) 2003-03-31
US6562349B1 (en) 2003-05-13
JP3429313B2 (ja) 2003-07-22
US5766608A (en) 1998-06-16

Similar Documents

Publication Publication Date Title
ATE226831T1 (de) Impfstoff gegen mittelohrentzündung
NO953033L (no) Stabile baktericid/permeabilitetsökende proteinprodukter og farmasöytiske preparater inneholdende disse
MX9701025A (es) Genes de penicilina g acilasa mutados.
IL114809A0 (en) Mutant br96 antibodies
US6114148C1 (en) High level expression of proteins
US5786464C1 (en) Overexpression of mammalian and viral proteins
EP1421195A4 (de) OBERFLÄCHENEXPRESSIONSVEKTOREN MIT pgsBCA, DEM FÜR POLY-GAMMA-GLUTAMAT-SYNTHETASE CODIERENDEN GEN, SOWIE VERFAHREN ZUR EXPRESSION EINES ZIELPROTEINS AN DER OBERFLÄCHE EINES DEN VEKTOR BENUTZENDEN MIKROORGANISMUS
EP0804609A4 (de) NEUARTIGE AUF p53 ANSPRECHENDE GENE
ATE64619T1 (de) Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli.
DE69129604T2 (de) Mutierte beta-Lactamacylasegene
AU3055495A (en) Recombinant mersacidin and a method for production
AU8258591A (en) Human mk gene and protein sequence
HUP9800767A2 (hu) Kevésbé adszorbeálódó és jobban hidrolizáló szubtilizin DY variánsok
WO2000001831A3 (en) Proteases fused with variants of streptomyces subtilisin inhibitor
BG100939A (en) -1-antichymotrypsin analogues having elastase inhibitory activity
EP1251176A3 (de) Expressionssysteme, die selbstspaltende Fusionsproteine verwenden sowie ein reduzierendes Polypeptid
AUPP627498A0 (en) Novel peptides - i
DK0769056T3 (da) Ikke-splejsende verianter af gp350/220
WO2001044289A3 (en) Modified leukotoxin gene and protein
EP0846165A4 (de) Neue cystein-protease von filariiden nematoden, nuklöeinsäuremoleküle und ihre verwendungen
MXPA01011563A (es) Una novedosa proteina 5 relacionada al factro-h y anticuerpos relacionados.
AU3943095A (en) A gene from the bacterium rhodothermus marinus, coding for the amino acid sequence of dna-ligase, produced in escherichia coli or some other suitable host organism
WO2002026817A3 (en) 33521, a human guanine nucleotide exchange family member and uses thereof
ES2169045T3 (es) Acido nucleico que codifica una alfa-acetolactato-descarboxilasa y sus aplicaciones.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0699076

Country of ref document: EP

REN Ceased due to non-payment of the annual fee